This time around, we note that Belite Bio hired Hendrik Scholl as chief medical officer. Previously, he was director of the Institute of Molecular and Clinical Ophthalmology Basel and an ...
On Thursday, H.C. Wainwright maintained a Buy rating for Belite Bio, Inc (NASDAQ:BLTE) shares, with a steady price target of $60.00. The firm's analyst highlighted the recent advancements in the ...